Skip to main content

Table 3 Clinical characteristics of Group II patients before VPS and one weeks after VPS

From: Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure

Patient Before VPS one week after VPS P-value
CSF parametersopening pressure
 ≥ 25 mH2O(n, %) 33 (84.6%) 12 (30.8%) 0.000*
 CSF WBC count×106/l (med, range) 66 (4–620) 77 (0–993) 0.220
 ≥20 (n,%) 36 (80.0%) 41 (91.1%) 0.136
 CSF protein g/l (med, range) 0.67 (0.22–4.08) 2.29 (0.08–729) 0.000*
 CSF glucose mmol/l (med, range) 1.16 (0.01–3.47) 0.91 (0.01–4.86) 0.380
 CSF cryptococci count/ml (med, range) 9533 (0–263,000) 2066 (0–235,000) 0.019*
 CSF culture positive (+) (n, %) 19 (48.7%) 6 (15.4%) 0.002*
BMR staging (n = 39)    0.026*
 1 8 (20.5%) 14 (35.9%)  
 2 10 (25.6%) 14 (35.9%)  
 3 21 (53.8%) 11 (28.2%)  
Complications after VSP (n, %) NA 20 (44.4%) NA
 Fever 3 days after VPS NA 16 (35.6%) NA
 Over-shunting NA 2 (4.4%) NA
 Obstructed shunt NA 3 (6.7%) NA
 Secondary abdominal infection NA 1 (2.2%) NA
  1. VPS ventriculoperitoneal shunts, WBC white blood cell, med median, CSF cerebrospinal fluid, NA not available. Data are presented as median (range) or n (%). Categorical variables were analyzed by Chi-square test or Fisher’s exact test
  2. *P < 0.05